Vivos Inc. (RDGL)
OTCMKTS · Delayed Price · Currency is USD
0.0629
-0.00172 (-2.66%)
At close: Jun 18, 2026
Vivos Employees
Vivos had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$77,699
Profits / Employee
-$3,416,166
Market Cap
31.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | 0 | - | 1 | 0 |
| Mar 31, 2024 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2023 | 1 | 0 | - | 1 | 0 |
| Sep 30, 2023 | 1 | 0 | - | 1 | 0 |
| Jun 30, 2023 | 1 | 0 | - | 1 | 0 |
| Mar 31, 2023 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2022 | 1 | 0 | - | 1 | 0 |
| Sep 30, 2022 | 1 | 0 | - | 1 | 0 |
| Jun 30, 2022 | 1 | 0 | - | 1 | 0 |
| Mar 31, 2022 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2021 | 1 | 0 | - | 1 | 0 |
| Sep 30, 2021 | 1 | 0 | - | 1 | 0 |
| Jun 30, 2021 | 1 | - | - | 1 | 0 |
| Mar 31, 2021 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zomedica | 141 |
| PetVivo Holdings | 24 |
| Positron | 10 |
| ALR Technologies SG | 7 |
| Guided Therapeutics | 3 |
Vivos News
- 7 days ago - Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing - GlobeNewsWire
- 13 days ago - Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 4 months ago - Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites - GlobeNewsWire
- 4 months ago - Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 4 months ago - Vivos Inc Updates Human Therapy Progress in India - GlobeNewsWire
- 5 months ago - Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals - GlobeNewsWire
- 6 months ago - Vivos Inc Summarizes Progress in its Animal Therapy Division - GlobeNewsWire
- 6 months ago - Vivos Inc Summarzes Preogress in its Animal Therapy Division - GlobeNewsWire